Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease

Annals of the American Thoracic Society

Volumn 12, Issue 5, 2015, Pages 742-751

  Deepak, Janaki A ^a,b   Ng, Xinyi ^c   Feliciano, Josephine ^a,d   Mao, Li ^d,e   Davidoff, Amy J ^f  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^f YALE UNIVERSITY   (United States)

Author keywords

Chronic obstructive pulmonary disease; Non small cell lung carcinoma; Pulmonology medicine; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INSTRUMENTAL VARIABLE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON SMALL CELL LUNG CANCER; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PULMONOLOGIST; CANCER REGISTRY; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL COMPETENCE; DISEASE MANAGEMENT; EPIDEMIOLOGY; FOLLOW UP; LUNG NEOPLASMS; MANPOWER; MORTALITY; ODDS RATIO; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL COMPETENCE; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY MEDICINE; RETROSPECTIVE STUDIES; RISK FACTORS; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES;

EID: 84929628173     PISSN: 23296933     EISSN: 23256621     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201406-230OC     Document Type: Article

References (37)

1. Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS One 2011;6:e17479.
2. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al. SEER cancer statistics review 1975-2010. Based on November 2012 SEER data submission. April 2013 [accessed 2014 Jan 1]. Available from: http://seer.cancer.gov/csr/1975-2010/
3. Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, Ramalingam SS. Lung cancer in elderly patients: an analysis of the Surveillance, Epidemiology, and End Results database. J Clin Oncol 2007;25:5570-5577.
4. rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e278S-e313S.
5. Gross CP, Smith BD, Wolf E, Andersen M. Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer 2008;112:900-908.
6. Vest MT, Herrin J, Soulos PR, Decker RH, Tanoue L, Michaud G, Kim AW, Detterbeck F, Morgensztern D, Gross CP. Use of new treatment modalities for non-small cell lung cancer care in the medicare population. Chest 2013;143:429-435.
7. Seda G, Stafford CC, Parrish JS, Praske SP, Daheshia M. Chronic obstructive pulmonary disease and vascular disease delay timeliness of early stage lung cancer resectional surgery. COPD 2013;10:133-137.
8. Chadha AS, Ganti AK, Sohi JS, Sahmoun AE, Mehdi SA. Survival in untreated early stage non-small cell lung cancer. Anticancer Res 2005;25:3517-3520.
9. Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest 2007;132:193-199.
10. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). Cochrane Database Syst Rev 2001;(2):CD002935.
11. Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol 2010;95:32-40.
12. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage i non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010;28:5153-5159.
13. Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, Buchholz TA, Smith BD. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 2012;84:1060-1070.
14. Pan H, Simpson DR, Mell LK, Mundt AJ, Lawson JD. A survey of stereotactic body radiotherapy use in the United States. Cancer 2011;117:4566-4572.
15. Ramella S, Maranzano E, Frata P, Mantovani C, Lazzari G, Menichelli C, Navarria P, Pergolizzi S, Salvi F. Radiotherapy in Italy for non-small cell lung cancer: patterns of care survey. Tumori 2012;98:66-78.
16. Hurkmans CW, Cuijpers JP, Lagerwaard FJ, Widder J, van der Heide UA, Schuring D, Senan S. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol 2009;4:1.
17. th ed. Philadelphia: Lippincott, Williams and Wilkins; 2012. pp. 205-226.
18. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2191-2197.
19. Ritzwoller DP, Carroll NM, Delate T, Hornbrook MC, Kushi L, Aiello Bowles EJ, Freml JM, Huang K, Loggers ET. Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network. Lung Cancer 2012;78:245-252.
20. Sekine Y, Chiyo M, Iwata T, Yasufuku K, Furukawa S, Amada Y, Iyoda A, Shibuya K, Iizasa T, Fujisawa T. Perioperative rehabilitation and physiotherapy for lung cancer patients with chronic obstructive pulmonary disease. Jpn J Thorac Cardiovasc Surg 2005;53:237-243.
21. Harada H, Yamashita Y, Misumi K, Tsubokawa N, Nakao J, Matsutani J, Yamasaki M, Ohkawachi T, Taniyama K. Multidisciplinary team-based approach for comprehensive preoperative pulmonary rehabilitation including intensive nutritional support for lung cancer patients. PLoS One 2013;8:e59566.
22. Gaga M, Powell CA, Schraufnagel DE, Schonfeld N, Rabe K, Hill NS, Sculier JP. An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer. Am J Respir Crit Care Med 2013;188:503-507.
23. Deepak J, Ng X, Mao L, Davidoff A. Pulmonologist management of chronic obstructive pulmonary disease (COPD) and receipt of recommended treatment for newly diagnosed non-small cell lung cancer (NSCLC) [abstract]. Am J Respir Crit Care Med 2013;187:A3602.
24. Ng X, Deepak J, Davidoff A. The role of pulmonologist management of prevalent chronic obstructive pulmonary disease in treatment and outcomes for newly diagnosed lung cancer [abstract]. Presented at the Academy Health Research Meeting. 2013, Baltimore, MD.
25. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40:IV-3-IV-18.
26. Buccaneer, Inc. Chronic conditions data warehouse medicare administrative data user guide. Version 3.0. April 2014 [accessed 2015 Jan 1]. Available from: http://www.ccwdata.org/cs/groups/public/documents/document/ccw-userguide.pdf
27. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care 2002;40:IV-26-IV-35.
28. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
29. Davidoff AJ, Hurria A, Zuckerman IH, Lichtman SM, Pandya N, Hussain A, Hendrick F, Weiner JP, Ke X, Edelman MJ. A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. J Geriatr Oncol 2013;4:157-165.
30. Owonikoko TK, Ragin C, Chen Z, Kim S, Behera M, Brandes JC, Saba NF, Pentz R, Ramalingam SS, Khuri FR. Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis. Oncologist 2013;18:600-610.
31. Fergusson RJ, Thomson CS, Brewster DH, Brown PH, Milroy R. Lung cancer: the importance of seeing a respiratory physician. Eur Respir J 2003;21:606-610.
32. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-742.
33. Sharif R, Cuevas CR, Wang Y, Arora M, Sharma G. Guideline adherence in management of stable chronic obstructive pulmonary disease. Respir Med 2013;107:1046-1052.
34. Sandhu SK, Chu J, Yurkovich M, Harriman D, Taraboanta C, Fitzgerald JM. Variations in the management of acute exacerbations of chronic obstructive pulmonary disease. Can Respir J 2013;20:175-179.
35. Wijayaratne K, Wilson J, Sivakumaran P, Sriram KB. Differences in care between general medicine and respiratory specialists in the management of patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Thorac Med 2013;8:197-203.
36. Mehta AJ, Macklis RM. Overview of accountable care organizations for oncology specialists. J Oncol Pract 2013;9:216-221.
37. National Cancer Institute. SEER-Medicare linked database [accessed 12/25/11]. Available from: http://healthcaredelivery.cancer.gov/seermedicare/